These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 16463437

  • 1. Prospective observational analysis of the efficacy and safety of low-dose (3 mg/kg) infliximab in ankylosing spondylitis: 4-year followup.
    Keeling S, Oswald A, Russell AS, Maksymowych WP.
    J Rheumatol; 2006 Mar; 33(3):558-61. PubMed ID: 16463437
    [Abstract] [Full Text] [Related]

  • 2. Low-dose infliximab treatment for ankylosing spondylitis--clinically- and cost-effective.
    Jois RN, Leeder J, Gibb A, Gaffney K, Macgregor A, Somerville M, Scott DG.
    Rheumatology (Oxford); 2006 Dec; 45(12):1566-9. PubMed ID: 16705043
    [Abstract] [Full Text] [Related]

  • 3. Infliximab treatment in ankylosing spondylitis: an observational study.
    Nikas SN, Alamanos Y, Voulgari PV, Pliakou XI, Papadopoulos CG, Drosos AA.
    Ann Rheum Dis; 2005 Jun; 64(6):940-2. PubMed ID: 15564309
    [Abstract] [Full Text] [Related]

  • 4. Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years.
    Braun J, Baraliakos X, Brandt J, Listing J, Zink A, Alten R, Burmester G, Gromnica-Ihle E, Kellner H, Schneider M, Sörensen H, Zeidler H, Sieper J.
    Rheumatology (Oxford); 2005 May; 44(5):670-6. PubMed ID: 15757965
    [Abstract] [Full Text] [Related]

  • 5. Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety.
    Maksymowych WP, Jhangri GS, Lambert RG, Mallon C, Buenviaje H, Pedrycz E, Luongo R, Russell AS.
    J Rheumatol; 2002 May; 29(5):959-65. PubMed ID: 12022358
    [Abstract] [Full Text] [Related]

  • 6. A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis.
    Inman RD, Maksymowych WP, CANDLE Study Group.
    J Rheumatol; 2010 Jun; 37(6):1203-10. PubMed ID: 20231198
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).
    van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, Braun J, Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group.
    Arthritis Rheum; 2005 Feb; 52(2):582-91. PubMed ID: 15692973
    [Abstract] [Full Text] [Related]

  • 8. Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis.
    Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, Gromnica-Ihle E, Kellner H, Schneider M, Sörensen H, Zeidler H, Sieper J.
    Ann Rheum Dis; 2005 Feb; 64(2):229-34. PubMed ID: 15388511
    [Abstract] [Full Text] [Related]

  • 9. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response.
    Braun J, Baraliakos X, Listing J, Fritz C, Alten R, Burmester G, Krause A, Schewe S, Schneider M, Sörensen H, Zeidler H, Sieper J.
    Ann Rheum Dis; 2008 Mar; 67(3):340-5. PubMed ID: 17967831
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period.
    Braun J, Deodhar A, Dijkmans B, Geusens P, Sieper J, Williamson P, Xu W, Visvanathan S, Baker D, Goldstein N, van der Heijde D, Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group.
    Arthritis Rheum; 2008 Sep 15; 59(9):1270-8. PubMed ID: 18759257
    [Abstract] [Full Text] [Related]

  • 11. Therapeutic efficacy and safety of multiple intravenous infusions of infliximab in refractory ankylosing spondylitis patients with axial involvement.
    Rejón E, Giménez MD, Mayordomo L, Rodríguez S, González MP, Marenco JL.
    Scand J Rheumatol; 2004 Sep 15; 33(5):323-6. PubMed ID: 15513681
    [Abstract] [Full Text] [Related]

  • 12. The cost-effectiveness of infliximab (Remicade) in the treatment of ankylosing spondylitis in Canada.
    Kobelt G, Andlin-Sobocki P, Maksymowych WP.
    J Rheumatol; 2006 Apr 15; 33(4):732-40. PubMed ID: 16583476
    [Abstract] [Full Text] [Related]

  • 13. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial.
    Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, Golder W, Gromnica-Ihle E, Kellner H, Schneider M, Sörensen H, Zeidler H, Reddig J, Sieper J.
    Arthritis Rheum; 2003 Aug 15; 48(8):2224-33. PubMed ID: 12905476
    [Abstract] [Full Text] [Related]

  • 14. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab.
    Brandt J, Haibel H, Cornely D, Golder W, Gonzalez J, Reddig J, Thriene W, Sieper J, Braun J.
    Arthritis Rheum; 2000 Jun 15; 43(6):1346-52. PubMed ID: 10857793
    [Abstract] [Full Text] [Related]

  • 15. Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis.
    Baraliakos X, Listing J, Rudwaleit M, Brandt J, Alten R, Burmester G, Gromnica-Ihle E, Haibel H, Schewe S, Schneider M, Sörensen H, Zeidler H, Visvanathan S, Sieper J, Braun J.
    J Rheumatol; 2007 Mar 15; 34(3):510-5. PubMed ID: 17299842
    [Abstract] [Full Text] [Related]

  • 16. Treatment of refractory inflammatory monoarthritis in ankylosing spondylitis by intraarticular injection of infliximab.
    Schatteman L, Gyselbrecht L, De Clercq L, Mielants H.
    J Rheumatol; 2006 Jan 15; 33(1):82-5. PubMed ID: 16292792
    [Abstract] [Full Text] [Related]

  • 17. Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years--early clinical response predicts long-term outcome.
    Baraliakos X, Listing J, Fritz C, Haibel H, Alten R, Burmester GR, Krause A, Schewe S, Schneider M, Sörensen H, Schmidt R, Sieper J, Braun J.
    Rheumatology (Oxford); 2011 Sep 15; 50(9):1690-9. PubMed ID: 21672969
    [Abstract] [Full Text] [Related]

  • 18. Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study.
    Marzo-Ortega H, McGonagle D, Jarrett S, Haugeberg G, Hensor E, O'connor P, Tan AL, Conaghan PG, Greenstein A, Emery P.
    Ann Rheum Dis; 2005 Nov 15; 64(11):1568-75. PubMed ID: 15829577
    [Abstract] [Full Text] [Related]

  • 19. Infliximab in severe active ankylosing spondylitis with spinal ankylosis.
    Cheung PP, Tymms KE, Wilson BJ, Shadbolt B, Brook AS, Dorai Raj AK, Khoo KB.
    Intern Med J; 2008 Jun 15; 38(6):396-401. PubMed ID: 18336538
    [Abstract] [Full Text] [Related]

  • 20. Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data.
    Baraliakos X, Brandt J, Listing J, Haibel H, Sörensen H, Rudwaleit M, Sieper J, Braun J.
    Arthritis Rheum; 2005 Dec 15; 53(6):856-63. PubMed ID: 16342093
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.